Diaphragmatic excursion correlates with exercise capacity and dynamic hyperinflation in COPD patients
- PMID: 33447614
- PMCID: PMC7792831
- DOI: 10.1183/23120541.00589-2020
Diaphragmatic excursion correlates with exercise capacity and dynamic hyperinflation in COPD patients
Abstract
Background: Although the pathophysiological mechanisms involved in the development of dyspnoea and poor exercise tolerance in patients with COPD are complex, dynamic lung hyperinflation (DLH) plays a central role. Diaphragmatic excursions can be measured by ultrasonography (US) with high intra- and interobserver reliability. The objective of this study was to evaluate the effect of diaphragmatic excursions as assessed by US on exercise tolerance and DLH in patients with COPD.
Methods: Patients with COPD (n=20) and age-matched control subjects (n=20) underwent US, which was used to determine the maximum level of diaphragmatic excursion (DEmax). Ventilation parameters, including the change in inspiratory capacity (ΔIC), were measured in the subjects during cardiopulmonary exercise testing (CPET). We examined the correlations between DEmax and the ventilation parameters.
Results: The DEmax of patients with COPD was significantly lower than that of the controls (45.0±12.8 mm versus 64.6±6.3 mm, respectively; p<0.01). The perception of peak dyspnoea (Borg scale) was significantly negatively correlated with DEmax in patients with COPD. During CPET, oxygen uptake/weight (V'O2 /W) and minute ventilation (V'E) were significantly positively correlated with DEmax, while V'E/V'O2 and V'E/carbon dioxide output (V'CO2 ) were significantly negatively correlated with DEmax in patients with COPD. DEmax was also significantly positively correlated with ΔIC, reflecting DLH, and with V'O2 /W, reflecting exercise capacity.
Conclusion: Reduced mobility of the diaphragm was related to decreased exercise capacity and increased dyspnoea due to dynamic lung hyperinflation in COPD patients.
Copyright ©ERS 2020.
Conflict of interest statement
Conflict of interest: M. Shiraishi has nothing to disclose. Conflict of interest: Y. Higashimoto has nothing to disclose. Conflict of interest: R. Sugiya has nothing to disclose. Conflict of interest: H. Mizusawa has nothing to disclose. Conflict of interest: Y. Takeda has nothing to disclose. Conflict of interest: S. Fujita has nothing to disclose. Conflict of interest: O. Nishiyama has nothing to disclose. Conflict of interest: S. Kudo has nothing to disclose. Conflict of interest: T. Kimura has nothing to disclose. Conflict of interest: Y. Chiba has nothing to disclose. Conflict of interest: K. Fukuda has nothing to disclose. Conflict of interest: Y. Tohda reports grants from Kyorin Pharmaceutical, MeijiSeika Pharma, Boehringer Ingelheim, Teijin Pharma, DaiichiSankyo, Astellas andPearl outside the submitted work.
Figures




References
LinkOut - more resources
Full Text Sources